Correlation between serum level of chemokine (C-C motif) ligand 18 and poor prognosis in breast cancer

Abstract

ABSTRACT. In this study, we investigated the correlation between serum chemokine (C-C motif) ligand 18 (CCL-18) and the prognosis as well as clinical characteristics of breast cancer. Blood samples from 207 breast cancer patients, 126 individuals with benign breast tumors, and 93 healthy women were collected. Serum CCL-18 expression was detected by enzyme-linked immunosorbent assay. Mann-Whitney's U tests were carried out to analyze the relationship between serum CCL-18 and clinicopathological variables. The Kaplan-Meier method was used to evaluate the overall survival (OS), whereas differences between groups were analyzed by log-rank tests. The COX proportional hazard regression model was used to determine the association between clinicopathological characteristics and survival. We found that serum CCL-18 was significantly higher in breast cancer patients (290.06 ± 89.52 pg/mL) as compared to that in individuals with benign tumors (170.14 ± 26.57 pg/mL) or healthy women (119.36 ± 38.77 pg/mL) (P < 0.05). Serum CCL-18 was correlated with clinical cancer stages (P = 0.007), and was associated with advanced cancer stage (P < 0.05).The 5-year OS rate of breast cancer patients with high serum CCL-18 was 35.9% (HR = 3.908, 95%CI = 2.546-12.090, P < 0.05), which was significantly lower as compared to that for patients with low serum CCL-18 (85.5%). Based on our results, we conclude that CCL-18 is a prognostic biomarker in patients with advanced breast cancer in Chinese patients.

Dysregulation of CCL18/CCR8 axis predicts poor prognosis in patients with gastric cancer

“…27 CCL18 acts as a biomarker, 9,10 associated with poor prognosis as an independent factor in cancer patients. 11,12 In this study, in consistence with previous results, 21 we found that CCL18 high expression had an association with tumor recurrence, but had no correlation with OS in patients with GC. Multivariate analysis revealed CCL18 as an independent prognostic factor of tumor recurrence in patients with GC.…”

“…5 Some studies show that the expression of CCL18 is increased in diffuse large B-cell lymphoma, 6 advanced breast cancer, 7 and low-grade endometrial cancer. 8 In addition, the serum level of CCL18 is elevated in epithelial ovarian cancer 9 and bladder cancer, 10 acting as a potential biomarker in these patients, 9,10 and associates with poor prognosis as an independent factor in patients with breast cancer 11 and colorectal cancer. 12 Moreover, CCL18 is involved in promoting cell proliferation, epithelial–mesenchymal transition (EMT), invasion and metastasis and repressing cell apoptosis in lymphoma, 6 pancreatic ductal adenocarcinoma, 13 breast cancer, 14 and lung cancer.…”

The serum level of CC chemokine ligand 18 correlates with the prognosis of non-small cell lung cancer

“…For example, Wu et al 23 found that the serum level of CCL18 in patients with gastric cancer was obviously higher than that of the control group; Sun and his coauthors revealed that the elevated serum level of CCL18 was associated with worse prognosis in female patients with breast cancer. 9 Likewise, Plönes et al 24 also indicated that the level of serum CCL18 was increased in NSCLC patients and predicted a diminished survival time in adenocarcinomas. However, Yuan et al 13 found that a high CCL18 level was significantly correlated with a better overall survival in colorectal cancer patients, which we consider may be related to the tissue specificity of CCL18 expression.…”

“…We have previously found that the level of CCL18 expression was significantly elevated in NSCLC tissues, which correlated with tumor stage and lymph node metastasis. 14 Similarly, numerous studies have shown that increased expression of CCL18 was observed in a variety of cancers and is associated with their clinical pathological features, including oral squamous cell carcinoma, 15 colorectal cancer, 13 ovarian cancer, 16 breast cancer, 9 bladder cancer, 17 and so on. Recently, Eriksson Hogling et al 18 showed that circulating and WAT-secreted CCL18 was correlated with such metabolic risk factors as insulin resistance and metabolic risk score in women.…”

“…8 In addition, numerous studies have shown that overexpression of CCL18 played an important role in the malignant progression and was closely related to a poor prognosis in various malignancies, including breast, ovarian, bladder, pancreatic, and colorectal cancers. 9-13 Furthermore, our previous study revealed that expression of CCL18 was significantly elevated in NSCLC tissues compared with that in adjacent normal lung tissues, whereby the high expression of CCL18 was correlated with tumor stage and lymph node metastasis. 14 In the present study, we further determined the serum level of CCL18 in NSCLC patients and evaluated its potential use as a biomarker for the prognosis of these patients.…”